Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.
Diffuse Large B Cell Lymphoma|Age Over 80 Years
DRUG: lenalidomide combined with rituximab
ORR, Overall response rate, 24 months
CR, Complete response, 24 months|OS, Overall survival, from date of treatment until the date of death from any cause, assessed up to 5 years|PFS, Progression-free survival, from date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.